Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

The New England journal of medicine - 29 Mar 2018

Tam Constantine S, Anderson Mary Ann, Pott Christiane, Agarwal Rishu, Handunnetti Sasanka, Hicks Rodney J, Burbury Kate, Turner Gillian, Di Iulio Juliana, Bressel Mathias, Westerman David, Lade Stephen, Dreyling Martin, Dawson Sarah-Jane, Dawson Mark A, Seymour John F, Roberts Andrew W

Abstract excerpt

BACKGROUND: Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as monotherapy in the treatment of mantle-cell lymphoma. Complete response rates of 21% have been observed for each agent when administered as long-term continuous therapy. Preclinical models predict synergy in combination. METHODS: We conducted a single-group, phase 2 study of daily oral ibrutinib and venetoclax in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Agammaglobulinaemia Tyrosine Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Marrow Examination

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Lymphoma, Mantle-Cell

Share to Neoplasm, Residual

Share to Piperidines

Share to Pyrazoles

Source

Identifiers

PMID: 29590547
DOI: 10.1056/NEJMoa1715519

Genes

BCL2
BTK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.PMID 29590547Read ↗

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.Semantic proximity Read ↗

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.Semantic proximity Read ↗

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.Semantic proximity Read ↗

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.Semantic proximity Read ↗

Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.Semantic proximity Read ↗

Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell LymphomaSemantic proximity Read ↗

Rocbrutinib in Covalent BTK Inhibitor Exposed Relapsed or Refractory Mantle Cell Lymphoma: a Phase 2, Open-label, Multicenter, Single-arm StudySemantic proximity Read ↗

BTK Inhibitors and BTK Degraders for the Treatment of Mantle Cell Lymphoma - Current Status and PerspectivesSemantic proximity Read ↗

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulationSemantic proximity Read ↗

Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRDSemantic proximity Read ↗

Dual targeting of BTK and BCL2 enhances apoptosis in marginal zone lymphoma models: preclinical activity of BGB-16673 and sonrotoclaxSemantic proximity Read ↗

Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclaxSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.